Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.
Unternehmen & Branche
| Name | Opus Genetics, Inc. |
|---|---|
| Ticker | IRD |
| CIK | 0001228627 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 338,4 Mio. USD |
| Beta | 0,52 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 14,196,000 | -49,591,000 | -0.80 | 50,243,000 | 15,348,000 |
| 2025-09-30 | 10-Q | 3,079,000 | -17,454,000 | -0.25 | 36,122,000 | 5,967,000 |
| 2025-06-30 | 10-Q | 2,882,000 | -7,420,000 | -0.12 | 38,665,000 | 17,473,000 |
| 2025-03-31 | 10-Q | 4,370,000 | -8,194,000 | -0.24 | 48,167,000 | 5,073,000 |
| 2024-12-31 | 10-K | 10,992,000 | -57,532,000 | -2.15 | 36,862,000 | 6,724,000 |
| 2024-09-30 | 10-Q | 3,867,000 | -7,526,000 | -0.29 | 40,389,000 | 34,300,000 |
| 2024-06-30 | 10-Q | 1,112,000 | -7,765,000 | -0.30 | 44,834,000 | 40,636,000 |
| 2024-03-31 | 10-Q | 1,711,000 | -7,106,000 | -0.29 | 51,844,000 | 46,057,000 |
| 2023-12-31 | 10-K | 19,049,000 | -9,986,000 | -0.46 | 53,948,000 | 49,906,000 |
| 2023-09-30 | 10-Q | 11,935,000 | 5,561,000 | 0.25 | 54,191,000 | 50,282,000 |
| 2023-06-30 | 10-Q | 3,674,000 | -4,961,000 | -0.24 | 43,465,000 | 37,704,000 |
| 2023-03-31 | 10-Q | 1,749,000 | -5,791,000 | -0.28 | 45,404,000 | 41,250,000 |
| 2022-12-31 | 10-K | 39,850,000 | 17,888,000 | 0.87 | 48,992,000 | 46,239,000 |
| 2022-09-30 | 10-Q | 0 | -4,531,000 | -0.22 | 14,568,000 | 11,877,000 |
| 2022-06-30 | 10-Q | 0 | -4,927,000 | -0.25 | 17,899,000 | 14,595,000 |
| 2022-03-31 | 10-Q | 0 | -6,595,000 | -0.35 | 20,485,000 | 17,272,000 |
| 2021-12-31 | 10-K | 589,000 | -56,693,000 | -3.82 | 26,077,000 | 22,222,000 |
| 2021-09-30 | 10-Q | 489,000 | -4,230,000 | -0.25 | 23,204,000 | 20,566,000 |
| 2021-06-30 | 10-Q | 100,000 | -7,136,000 | -0.52 | 25,252,000 | 22,553,000 |
| 2021-03-31 | 10-Q | -39,014,000 | -3.57 | 12,126,000 | 9,816,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-23 | Magrath George | Director, Officer, Chief Executive Officer | Open Market Sale | -9,511 | 5.22 | -49,647.42 | -6,1% | |
| 2026-04-23 | Jayagopal Ashwath | Officer, Chief Scientific & Dev. Ofc. | Open Market Sale | -7,542 | 5.19 | -39,155.80 | -4,8% | |
| 2026-04-23 | Gagnon Robert E. | Officer, Chief Financial Officer | Open Market Sale | -7,842 | 5.18 | -40,657.63 | -5,0% | |
| 2026-04-23 | YERXA BENJAMIN R | Director, Officer, President | Open Market Sale | -7,470 | 5.24 | -39,121.14 | -4,8% | |
| 2026-04-23 | Zaremba Rabourn Amy | Officer, Head of Fin. Quality Assurance | Open Market Sale | -1,641 | 5.20 | -8,539.76 | -1,0% | |
| 2026-04-23 | SCHACHLE JOSEPH K | Officer, Chief Operating Officer | Open Market Sale | -4,697 | 5.22 | -24,519.28 | -3,0% | |
| 2026-03-16 | Zaremba Rabourn Amy | Officer, Head of Fin. Quality Assurance | Open Market Sale | -2,816 | 5.25 | -14,769.92 | -1,8% | |
| 2026-03-16 | SCHACHLE JOSEPH K | Officer, Chief Operating Officer | Open Market Sale | -3,719 | 5.25 | -19,525.12 | -2,4% | |
| 2026-03-16 | Magrath George | Director, Officer, Chief Executive Officer | Open Market Sale | -24,438 | 5.21 | -127,326.87 | -15,6% | |
| 2026-03-16 | Jayagopal Ashwath | Officer, Chief Scientific & Dev. Ofc. | Open Market Sale | -3,719 | 5.12 | -19,046.11 | -2,3% | |
| 2025-12-09 | Foundation Fighting Blindness Retinal Degeneration Fund | Director | Open Market Sale | -4,000,000 | 2.15 | -8,600,000.00 | -1053,2% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.